Absci Corporation

NasdaqGS ABSI

Absci Corporation Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024: USD -398.00 K

Absci Corporation Capital Expenditure is USD -398.00 K for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Absci Corporation Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -23.93 M, a 21.92% change year over year.
Absci Corporation Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -30.65 M.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGS: ABSI

Absci Corporation

CEO	Mr. Sean McClain
IPO Date	July 22, 2021
Location	United States
Headquarters	18105 SE Mill Plain Boulevard
Employees	155
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Fintech

Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Key trends

Past 5 years